<DOC>
	<DOCNO>NCT01552954</DOCNO>
	<brief_summary>Purpose study 1 . Intensive education low salt diet enhance anti-proteinuric effect Olmesartan , popular anti-hypertensive drug angiotensin II receptor blocker , Koreans compare conventional prescription medication . 2 . Intensive education low salt diet decrease amount 24 hour-urine sodium excretion compare control group , effectively .</brief_summary>
	<brief_title>Effects Low Sodium Intake Anti-proteinuric Efficacy Hypertensive Patient With Olmesartan</brief_title>
	<detailed_description>1 . Background A . The chronic kidney disease ( CKD ) one main burden chronic disease prevalence CKD increase worldwide . In Korea , prevalence CKD report 13.7 % among urban Korean adult 2008 study group . B . It well know CKD important risk factor cardiovascular event , cardiovascular mortality , cause-mortality , hospitalization . The cost management CKD high take 3.25 % budget medical reimbursement 2004 Koreans , rank top expenditure single disease category . C. The popular risk factor CKD progression age , obesity , hyperlipidemia , diabetes mellitus , hypertension , proteinuria . The hypertension proteinuria also cause cardiovascular event increase mortality rate . D. The inhibitor renin-angiotensin aldosterone system , angiotensin II type I receptor blocker ( ARB ) angiotensin convert enzyme inhibitor ( ACEI ) , well know medication prevent cardiovascular event renal functional deterioration end stage renal disease ( ESRD ) patient hypertension , non-diabetic CKD , diabetic nephropathy . One adverse event ARB decrease hemoglobin . Inoue et al report level hemoglobin decrease amount 0.45 ±0.89 g/dL prescription ARB valsartan decrease erythropoietin 6 day medication . The exact mechanism decrease hemoglobin ARB fully verify related decrease effect angiotensin II aggravate hypoxia kidney activation hypoxia-inducible factor 1α ( HIF1a ) decrease production erythropoietin report Durmus et al . Considering relationship ARB usage decrease proteinuria transplant kidney , aggravation hypoxia HIF1a CKD , ARB decrease HIF1a erythropoietin ( EPO ) , could postulate decrease hemoglobin would adverse effect ARB deteriorate patient ' condition co-phenomenon ARB 's anti-RAS effect marker ARB 's effectiveness . E. The anti-proteinuric effect ARB decrease high salt intake . For example , ARB treatment without low salt intake decreased proteinuria 30 % patient proteinuria 2-10g/day compare baseline value addition low salt diet ARB treatment decrease proteinuria 25 % . But , use slow salt tablet , increase daily intake sodium diminish anti-proteinuric effect ARB diabetic nephropathy . F. The previous study effect ARB proteinuria affect sodium intake take method control diet researcher use slow salt tablet method practical adopt real clinical practice . G. The moderate mild decrease daily sodium intake low daily excretion sodium 55 mEq/day effect decrease proteinuria 11 % hypertensive patient . H. The mean amount sodium Korean diet report high 208 mmol/day Intersalt study , 11 g salt . The recent report also show trend high salt-intake Koreans . 2 . Rationale So , It worth study - high salt intake prevalent Koreans , - high salt diet diminishes effect ARB proteinuria - method use previous study suitable apply clinical practice , - study reveal decrease hemoglobin would marker effect ARB adverse event ARB . 3 . Objectives 1 . Primary objective : The difference amount albuminuria usage Olmesartan amount albuminuria prescription Olmesartan intensive diet education intervention group high difference albuminuria control group . 2 . Secondary objective : Item 1 : In patient , Olmesartan decrease albuminuria . Item 2 : In patient , change hemoglobin prescription Olmesartan proportional change albuminuria serum erythropoietin . Item 3 : Intensive education low salt diet induces significant decrease daily sodium excretion Intervention group compare control group . Item 4 : Intensive education low salt diet induces significant decrease blood pressure Intervention group compare control group . 4 . Study Flow - Period 1 . Washout period ( -8 week ; Point 0 0 week ; Point 1 ) 2 . Olmesartan Period ( 0 week ; point 1 8 week ; point 2 ) 3 . Intervention period ( 8 week ; point 2 16 week ; point 3 ) - For patient take ACEI , ARB , diuretic , renin inhibitor , already ; Initial wash-out period 8 week , ( point 1 ) prescription Olmesartan 40 mg qd 8 week , ( point 2 ) allocation Intensive group control group 8 week , study ( point 3 ) . - For patient without take ACEI , ARB , diuretic , renin inhibitor ; For initial 8 week , adjust blood pressure around 140/90 mmHg , ( point 1 ) prescription Olmesartan 40 mg qd 8 week , ( point 2 ) allocation Intensive group control group 8 week , study ( point 3 ) . - Blood pressure control Adjust blood pressure around 140/90 mmHg hypertensive drug except ACEI , ARB , diuretic , renin inhibitor whole period . - Intensive diet education : For 8 week , dietitian call patient take information accord pre-defined questionnaire , check daily diet habit daily food take , guide lessen sodium intake 30 min call . The call do week 8 week .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<criteria>Aged 19 year 75 year less Hypertension patient : Patients whose blood pressure 140/90mmHg , patient newly diagnose hypertension prescribe antihypertensive medication . Hypertensive patient verify 2 time albuminuria 30 mg/g cr spot urine sample interval 1 week recent 6 month Estimated glomerular filtration rate ( GFR ) Modification Diet Renal Disease ( MDRD ) equation 30 ml/min/1.73 m2 Patients give write consent study oneself Blood pressure 160/100 mmHg Pregnant Serum potassium level 5.5 mEq/L screen period Patients malignancy , acute cerebral infarction , acute myocardial infarction , unstable angina , percutaneous coronary arterial intervention ( PCI ) , coronary artery bypass graft ( CABG ) recent 6 month Patients diabetes mellitus Patients allergy Olmesartan Patients involve clinical trial recent 1 month participate screening period Patients take medication ( ) corticosteroid immunosuppressant screening period</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>hypertension</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>albuminuria</keyword>
	<keyword>low salt diet</keyword>
	<keyword>Angiotensin II receptor blocker</keyword>
</DOC>